Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTGDN8)

Drug Name
Levetiracetam Drug Info
Synonyms
102767-28-2; Keppra; (S)-2-(2-Oxopyrrolidin-1-yl)butanamide; Keppra XR; Levetiracetamum; ucb L059; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; UCB-L 059; UCB-L059; Spritam; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; SIB-S1; UNII-44YRR34555; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-; UCB-22059; Levetiracetamum [INN-Latin]; Levetiractam; CHEBI:6437; ucb L060; Levetiracetam In Sodium Chloride; 44YRR34555; Levroxa; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-,; Keppra; Leviteracetam; Torleva; Levetiracetam [INN]; Ucb L060; Etiracetam levo-isomer; Keppra (TN); L-059; Etiracetam, S-isomer; Keppra, Keppra XR),Levetiracetam; Levetriacetam
Indication
Disease Entry ICD 11 Status REF
Epilepsy 8A60-8A68 Approved [1]
Fibromyalgia MG30.01 Approved [2]
Therapeutic Class
Anticonvulsants
Cross-matching ID
PubChem CID
5284583
ChEBI ID
CHEBI:6437
CAS Number
CAS 102767-28-2
TTD Drug ID
DMTGDN8
VARIDT Drug ID
DR00180
ACDINA Drug ID
D00358

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting 5-HT 3A receptor (HTR3A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dolasetron DMMG26Z Nausea MD90 Approved [8]
Alosetron DML2A03 Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [9]
Tropisetron DMNSJ7V Fibromyalgia MG30.01 Approved [2]
Palonosetron DMBHMOX Nausea MD90 Approved [10]
Procaine DM4LSNE Anaesthesia 9A78.6 Approved [11]
Cilansetron DMP0NGX Irritable bowel syndrome DD91.0 Phase 3 [12]
BEMESETRON DMSPJX9 N. A. N. A. Discontinued in Phase 3 [13]
Norcisapride DMJSKUI Gastroesophageal reflux disease DA22.Z Discontinued in Phase 2 [14]
YM-114 DML2IXO Nausea MD90 Discontinued in Phase 2 [15]
ATI-17000 DMZJVR5 Irritable bowel syndrome DD91.0 Preclinical [16]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Synaptic vesicle glycoprotein 2A (SV2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Brivaracetam DMSEPK8 Complex partial seizure 8A68.0 Approved [17]
Padsevonil DMRZ1F2 Epilepsy 8A60-8A68 Phase 2/3 [18]
Seletracetam DM3IJMN Epilepsy 8A60-8A68 Discontinued in Phase 3 [19]
Drug(s) Transported By P-glycoprotein 1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [20]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [21]
Methotrexate DM2TEOL Anterior urethra cancer Approved [22]
Folic Acid DMEMBJC Colorectal carcinoma Approved [23]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [22]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [22]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [24]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [22]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [25]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [26]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flupentixol DM0DJ9O Schizophrenia 6A20 Approved [27]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [28]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [29]
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [6]
Cepharanthine DM9Y5JB N. A. N. A. Approved [30]
Itraconazole DMCR1MV Aspergillosis 1F20 Approved [31]
Clozapine DMFC71L Schizophrenia 6A20 Approved [32]
Midostaurin DMI6E0R Acute myeloid leukaemia 2A60 Approved [33]
Trifluoperazine DMKBYWI Anxiety Approved [34]
Olanzapine DMPFN6Y Bipolar depression Approved [32]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Etretinate DM2CZFA Keratosis ED56 Approved [35]
FADROZOLE DM3C5GZ Breast cancer 2C60-2C65 Approved [36]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [37]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [38]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [39]
Testosterone DM7HUNW Hot flushes GA30 Approved [39]
Pyruvic acid DM7Q41G Malnutrition 5B50-5B71 Approved [40]
Topiramate DM82Z30 Alcohol dependence 6C40.2 Approved [41]
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [41]
ABIRATERONE DM8V75C Prostate cancer 2C82.0 Approved [42]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aromatase (CYP19A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Letrozole DMH07Y3 Estrogen-receptor positive breast cancer Approved [43]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [44]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [45]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [46]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [45]
Methotrexate DM2TEOL Anterior urethra cancer Approved [47]
FADROZOLE DM3C5GZ Breast cancer 2C60-2C65 Approved [36]
Bifonazole DM3KN7V Fungal infection 1F29-1F2F Approved [48]
Quercetin DM3NC4M Obesity 5B81 Approved [49]
Fluoxetine DM3PD2C Bipolar depression Approved [45]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2 (HSD3B2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [37]
Topiramate DM82Z30 Alcohol dependence 6C40.2 Approved [41]
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [41]
Lindane DMB8CNL Infestations of lice and scabies 1G00.Z Approved [50]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [5]
Metyrapone DMI7FVQ Cushing disease 5A70 Approved [51]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [37]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [52]
Pioglitazone DMKJ485 Amyotrophic lateral sclerosis 8B60.0 Approved [53]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [54]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Steroidogenic acute regulatory protein, mitochondrial (STAR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Etretinate DM2CZFA Keratosis ED56 Approved [35]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [55]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [56]
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [57]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [58]
Lindane DMB8CNL Infestations of lice and scabies 1G00.Z Approved [50]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [5]
Ethanol DMDRQZU Chronic pain MG30 Approved [59]
Hydrocortisone DMGEMB7 Acne vulgaris ED80 Approved [60]
Mifepristone DMGZQEF Cushing disease 5A70 Approved [61]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Serum paraoxonase/arylesterase 1 (PON1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Primidone DM0WX6I Epilepsy 8A60-8A68 Approved [7]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [62]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [63]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [64]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [65]
Quercetin DM3NC4M Obesity 5B81 Approved [66]
Panobinostat DM58WKG Chronic graft versus host disease Approved [67]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [68]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [69]
Gabapentin DM6T924 Complex partial seizure 8A68.0 Approved [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 3A receptor (HTR3A) TTPC4TU 5HT3A_HUMAN Antagonist [2]
Synaptic vesicle glycoprotein 2A (SV2A) TTT3P91 SV2A_HUMAN Modulator [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2 (HSD3B2) OT02MSKN 3BHS2_HUMAN Gene/Protein Processing [5]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Gene/Protein Processing [5]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Gene/Protein Processing [6]
Serum paraoxonase/arylesterase 1 (PON1) OTD0Z2XO PON1_HUMAN Gene/Protein Processing [7]
Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1) OTZKVLVJ CP17A_HUMAN Gene/Protein Processing [5]
Steroidogenic acute regulatory protein, mitochondrial (STAR) OTFEZ5AI STAR_HUMAN Gene/Protein Processing [5]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6826).
2 Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46.
5 Differential effects of antiepileptic drugs on steroidogenesis in a human in vitro cell model. Acta Neurol Scand Suppl. 2009;(189):14-21.
6 Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
7 Antiepileptic drugs: impacts on human serum paraoxonase-1. J Biochem Mol Toxicol. 2017 Jun;31(6).
8 Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24.
9 Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844.
10 Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34.
11 Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):462-70.
12 Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin Investig Drugs.2005 Feb;14(2):185-93.
13 Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem. 1992 Jan 24;35(2):310-9.
14 mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83.
15 Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol. 1995 Nov;69(3):205-14.
16 Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
17 Pharmacological management of epilepsy: recent advances and future prospects. Drugs. 2008;68(14):1925-39.
18 Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models. J Pharmacol Exp Ther. 2020 Jan;372(1):11-20.
19 Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
20 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
21 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
22 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
23 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
24 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
25 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
26 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
27 Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
28 Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
29 Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
30 Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
31 Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
32 Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
33 Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
34 Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
35 Retinoids and retinol differentially regulate steroid biosynthesis in ovarian theca cells isolated from normal cycling women and women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 Aug;90(8):4858-65. doi: 10.1210/jc.2005-0330. Epub 2005 May 24.
36 Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 10;48(5):1563-75.
37 Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity. J Mol Endocrinol. 2004 Apr;32(2):425-36.
38 Use of organ culture to study the human fetal testis development: effect of retinoic acid. J Clin Endocrinol Metab. 2006 Jul;91(7):2696-703.
39 Inhibition of CYP17 expression by adrenal androgens and transforming growth factor beta in adrenocortical cells. Acta Biochim Pol. 2004;51(4):907-17.
40 Phosphorylation of CtBP1 by cAMP-dependent protein kinase modulates induction of CYP17 by stimulating partnering of CtBP1 and 2. J Biol Chem. 2008 Mar 14;283(11):6925-34. doi: 10.1074/jbc.M708432200. Epub 2008 Jan 9.
41 Effects of anticonvulsants on human p450c17 (17alpha-hydroxylase/17,20 lyase) and 3beta-hydroxysteroid dehydrogenase type 2. Epilepsia. 2005 Mar;46(3):444-8.
42 A fission yeast-based test system for the determination of IC50 values of anti-prostate tumor drugs acting on CYP21. J Enzyme Inhib Med Chem. 2006 Oct;21(5):547-56.
43 Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res. 2005 Apr 15;11(8):2809-21. doi: 10.1158/1078-0432.CCR-04-2187.
44 Cannabidiol (CBD) but not tetrahydrocannabinol (THC) dysregulate in vitro decidualization of human endometrial stromal cells by disruption of estrogen signaling. Reprod Toxicol. 2020 Apr;93:75-82. doi: 10.1016/j.reprotox.2020.01.003. Epub 2020 Jan 14.
45 Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay. Toxicol In Vitro. 2015 Oct;29(7):1729-35.
46 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
47 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
48 Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans. Endocr Res. 2004 Aug;30(3):387-94.
49 Estrogen synthesis in human colon cancer epithelial cells. J Steroid Biochem Mol Biol. 1999 Dec 31;71(5-6):223-30.
50 Steroidogenic gene expression in H295R cells and the human adrenal gland: adrenotoxic effects of lindane in vitro. J Appl Toxicol. 2006 Nov-Dec;26(6):484-92.
51 The H295R system for evaluation of endocrine-disrupting effects. Ecotoxicol Environ Saf. 2006 Nov;65(3):293-305.
52 Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
53 Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2. Mol Pharmacol. 2007 Mar;71(3):787-98.
54 Prostaglandin E2 via steroidogenic factor-1 coordinately regulates transcription of steroidogenic genes necessary for estrogen synthesis in endometriosis. J Clin Endocrinol Metab. 2009 Feb;94(2):623-31.
55 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
56 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
57 Antiepileptic drugs are endocrine disruptors for the human fetal testis ex vivo. Toxicol Sci. 2023 Sep 28;195(2):169-183. doi: 10.1093/toxsci/kfad076.
58 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
59 Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
60 Glucocorticoid-activation system mediated glucocorticoid-insulin-like growth factor 1 (GC-IGF1) axis programming alteration of adrenal dysfunction induced by prenatal caffeine exposure. Toxicol Lett. 2019 Mar 1;302:7-17.
61 Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
62 Beneficial effect of oleoylated lipids on paraoxonase 1: protection against oxidative inactivation and stabilization. Biochem J. 2003 Oct 15;375(Pt 2):275-85.
63 Serum paraoxonase activity before and after treatment of thyrotoxicosis. Clin Endocrinol (Oxf). 2004 Jan;60(1):75-80.
64 Effects of some antibiotics on paraoxonase from human serum in vitro and from mouse serum and liver in vivo. Biol Pharm Bull. 2006 Aug;29(8):1559-63.
65 Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol. 2003 Nov 1;23(11):2083-9. doi: 10.1161/01.ATV.0000096207.01487.36. Epub 2003 Sep 18.
66 Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism. Mol Cell Biol. 2004 Jun;24(12):5209-22.
67 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
68 Transcriptional regulation of human paraoxonase 1 by PXR and GR in human hepatoma cells. Toxicol In Vitro. 2015 Dec 25;30(1 Pt B):348-54.
69 Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res. 2008 Oct;49(10):2142-8.